Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but the company hopes new data could help it gather momentum. The French ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

The products covered include Admelog, Lantus, Toujeo, Apidra and any biosimilar of those products that Sanofi markets in the U.S. “Insulin is life-sustaining medication and far too many Mainers ...

Types of insulin include rapid-, regular-, intermediate-, and long-acting, based on how long they take to start working. You may take a combination of these when managing type 2 diabetes.

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Mainers who rely on insulin will now be eligible to purchase ... The products covered include Admelog, Lantus, Toujeo, Apidra and any biosimilar of those products that Sanofi markets in the ...